On June 17, the "SY-617" cooperation signing ceremony for innovative Chinese medicine under development was held in the Guangdong Macao Cooperation Chinese Medicine Science and Technology Industrial Park (hereinafter referred to as the "Industrial Park"). The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Jiaheng (Zhuhai Hengqin) Medical Technology Co., Ltd. (hereinafter referred to as "Jiaheng Medicine") Zhuhai Hengqin Haomai Technology Co., Ltd. (hereinafter referred to as "Haomai Technology") and Yue'ao Pharmaceutical Co., Ltd. (hereinafter referred to as "Yue'ao Pharmaceutical") jointly signed a cooperation agreement.

It is reported that "SY-617 New Drug Research and Development" is a major scientific and technological project of Sichuan Administration of Traditional Chinese Medicine. This prescription is derived from the clinical experience of the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine and is mainly used for the prevention and treatment of Upper respiratory tract infection and respiratory infectious diseases. This prescription has a solid research foundation and reliable clinical efficacy, reflecting the characteristics of traditional Chinese medicine development that "originates from clinical practice and is used in clinical practice", and is in line with the current national advocacy for the development of new Chinese medicine drugs.

Jiaheng Pharmaceuticals is one of the key enterprises introduced in the cooperation zone. It is a research and development company under the wholly-owned subsidiary of Hong Kong listed company Fusen Pharmaceuticals, Fusen Macau Co., Ltd. It is the first drug research and development institution in the cooperation zone to obtain a drug production license. Using the MAH system, Jiaheng has held the only drug production approval (Yuanhu Zhitong Oral Liquid) in the cooperation zone. As of now, a total of 31 new Chinese medicine and chemical medicine projects have been signed and approved, with a cumulative contract amount of over 150 million yuan.

This signing marks the official entry into the implementation phase of the cooperation project, striving to become the first Class 1.1 innovative traditional Chinese medicine drug approved for IND (New Drug Clinical Trial Application) and NDA (New Drug Application) in the cooperation zone, which is of great significance for promoting the development of the biopharmaceutical and big health industries in the cooperation zone.

At the signing ceremony, Mi Yinjun, a member of the Party Group and Deputy Director of the Sichuan Provincial Administration of Traditional Chinese Medicine, stated that the "SY-617" project is the first new Chinese medicine under the "Sichuan Australia Traditional Chinese Medicine Industry Development Cooperation Framework Agreement". The implementation of this project in Hengqin has played an important exemplary role in the cooperation and development of the two traditional Chinese medicine industries.

Cao Zhiming, President of Fusen Pharmaceutical, stated that since its establishment, Jiaheng Pharmaceutical has received attention and support from relevant departments in the cooperation zone, laying a solid foundation for the company's scientific research work. Jiaheng Pharmaceutical will accelerate its research and development progress, and in the future, it will conduct special docking on the "SY-617" cooperation, accelerate the project process, and strive to become the first Class 1.1 innovative traditional Chinese medicine drug approved for IND and NDA in the cooperation zone.

Throughout the history, Sichuan and Australia have established a solid foundation of cooperation in traditional Chinese medicine prescriptions. In 2017, Macau and Sichuan signed the "Sichuan Macao Traditional Chinese Medicine Industry Development Cooperation Framework Agreement", and subsequently carried out cooperation in training and international registration for Portuguese speaking countries based on this agreement. In May of this year, the Industrial Park and the Sichuan Provincial Administration of Traditional Chinese Medicine jointly formed the "Sichuan Australia Delegation" to promote traditional Chinese medicine culture overseas. This signing is another innovative practice in promoting cooperation in the traditional Chinese medicine industry between Sichuan and Australia, helping to promote the high-quality development of the traditional Chinese medicine industry in Hengqin.

At present, the development of the biopharmaceutical and big health industries in the cooperation zone is gradually becoming large-scale, and the industrial space represented by the Guangdong Macao Cooperative Traditional Chinese Medicine Technology Industrial Park has preliminarily formed a gathering trend.

Last year, the cooperation zone introduced several targeted and supportive measures to support the high-quality development of the biopharmaceutical health industry in the Hengqin Guangdong Macao Deep Cooperation Zone, creating a full lifecycle support environment for the biopharmaceutical health enterprises in the cooperation zone, achieving full coverage from landing and entry to industrialization stage. With the promotion and construction of Qin'ao integration, the industrial supporting facilities and policy environment of the cooperation zone are becoming increasingly perfect, attracting more and more pharmaceutical companies to settle here.